|
Families of SMA has Funded the Following Research for the Quinazoline Program: 1) From 2000 to 2003 to Aurora Biosciences for $2,925,000 for "SMN2 Cell-Bassed Assay Development and Drug Screening on 558,000 Distinct Compounds". 2) From 2002 to 2005 to Medichem/deCODE Chemistry for $5,556,950 for "Medicinal Chemistry and Structure Activity Relationship Determination of 2,4-Diaminoquinazoline Compounds". 3) From 2005 to 2009 to Dr. Arthur Burghes at Ohio State University for $191,500 for "Quinazoline Drug Testing in SMA Mice." 4) In 2006 to Medichem/deCODE Chemistry for $991,819 for "Lead Optimization of 2,4-Diaminoquinazoline Compounds, including Assessment of ADME Properites, Drug Brain Levels, and Early Safety Testing". 5) In 2007 to Medichem/deCODE Chemistry for $1,209,140 for "Finalizing Lead Optimization, Clinical Candidate Selection, and IND -Enabling Studies (GLP 28-day General Toxicology studies, GLP Safety Pharmacology Studies, and GLP Genotoxicity Studies)". 6) From 2007 to 2009, Patent Costs of $211,500 for "Intellectual Property Protection of Quinazoline Compounds". 7) In 2007 to Paracelsus, Inc. for $18,000 for "Toxicology Consulting". 8) In 2008 to Medichem/deCODE Chemistry for $480,213 for "IND- Enabling Studies on Quinazonline495 (GLP 28-day General Toxicology studies, GLP Safety Pharmacology Studies, and GLP Genotoxicity Studies)". 9) In 2008 to Dr. Mike Kiledjian at Rutgers University for $80,000 for "Mechanism of Action for Drug Mediated Up-regulattion of SMN2". 10) In 2008 to Dr. Christine DiDonato at Children's Memorial Hospital for $18,000 for "Quinazoline495 Drug Testing in SMA Mice". 11) In 2008 to Dr. Wendy Chung at Columbia University for $15,300 for "SMN Gene Expression Analysis on Tissues from Quinazoline Treated SMA Mice". 12) In 2008 to Paracelsus, Inc. for $18,000 for "Toxicology Consulting". 13) in 2009 to Medichem/deCODE Chemistry for $22,000 for "IND Enabling Studies on Quinazonline495 (GLP 28-day General Toxicology studies, GLP Safety Pharmacology Studies, and GLP Genotoxicity Studies)". 14) In 2009 to Dr. Mike Kiledjian at Rutgers University for $214,000 for "Mechanism of Action for Drug Mediated Up-regulattion of SMN2". 15) In 2009 to Medicilon for $44,372 for "Rat and Dog Pharmacokinetic Studies on Quinazonline495". 16) In 2009 to Chantest for $60,480 for "Cardiac Safety IND-Enabling Studies on Quinazonline495". 17) In 2009 to Paracelsus, Inc. for $40,200 for "Toxicology and Regulatory Consulting". 18) In 2010 to Dr. Christine DiDonato at Children's Memorial Hospital for $54,000 for "Quinazoline495 Drug Testing in SMA Mice". Total Funding for the Quinazoline Program of $12,150,474.
| 
